Novo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.
Roche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.
The French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.
Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family office, an award bearing their name is turning that investment philosophy into a search for Europe’s next biotech builders.
Danish biotech ResoTher Pharma’s heart attack drug RTP-026 was well tolerated and showed early efficacy signals in a 66-patient Phase 2a trial, according to results announced Sept. 14 that clear a key condition for Swedish-listed Hunter Capital RTO 1’s planned reverse acquisition of the company.
GSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences in a deal worth up to $750 million (€650 million), its second purchase from the company in under two years.
Agomab Therapeutics’ inhaled idiopathic pulmonary fibrosis (IPF) drug AGMB-447 showed lung-restricted exposure and inhibited its intended target in its first patient trial. The company plans to move the ALK5 inhibitor into phase 2 before the end of the year.
MaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy.
French biotech Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the company enough encouragement to plan further development.
French biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease.